Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT05162222
- Locations
- 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05154136
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 766
- Registration Number
- NCT05150691
- Locations
- 🇺🇸
Kapi'olani Medical Center for Women and Children, Honolulu, Hawaii, United States
🇺🇸Women's Cancer Care, Covington, Louisiana, United States
🇺🇸Holy Cross Hospital, Silver Spring, Maryland, United States
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05134337
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Prospective Study on Optimizing Treatment for ABPA
- Conditions
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05129033
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole
- Conditions
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT05084651
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT05069870
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 28
- Registration Number
- NCT05064449
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05057949
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 74
- Registration Number
- NCT04981704
- Locations
- 🇺🇸
Celerion, Phoenix clinical facility, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.